HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Icy Hot SmartRelief Latest TENS Target Is Back Pain

This article was originally published in The Tan Sheet

Executive Summary

Chattem rolls out Icy Hot SmartRelief Back & Hip device for drug-free pain relief for sore or aching muscles, chronic pain and arthritis, the Sanofi subsidiary says. The Back & Hip and Knee & Shoulder products feature the same control unit but different electrode pads, with refills sold without a control unit.

You may also be interested in...



First-In-Class Nasacort OTC Also Originates ‘Children’s’ Label

Sanofi introduces Children’s Nasacort Allergy 24HR in the same formulation and dosage as the original OTC switch, but with “children’s” added to the package after approval by FDA. The firm promotes the product as the “first and only” 24-hour multi-symptom nasal allergy spray available OTC for children ages 2 and up.

PCPC Working To Ensure State EPR Programs Are ‘Least Onerous As Possible’

The Personal Care Products Council is engaging on state legislation for extended producer responsibility programs, which impose the cost of recycling plastic materials on manufacturers. Emerging bills to prohibit use of the ‘chasing arrows’ recycling symbol on consumer packaging also have the trade group’s attention.

PCPC Sees Opportunity For US Cosmetics Modernization After Congressional Mid-Terms

The Personal Care Products Council is pivoting to focus on passing cosmetics modernization legislation after mid-term congressional elections, while still hopeful the language could go through as part of FDA user-fee reauthorization. Karin Ross, executive VP, government affairs at PCPC, discussed the situation at the trade group’s Leadership Summit in Washington.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS123542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel